• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » TCT 2016: Stents, stents, stents on Day 1 » Page 5

TCT 2016: Stents, stents, stents on Day 1

October 31, 2016 By Brad Perriello

Polymer-free drug-coated stent bests bare-metal stent in high bleeding risk patients

Patients at a high risk for bleeding who took a 1-month course of dual anti-platelet therapy fared better with a polymer-free drug-coated stent than with a bare metal stent after 2 years, according to results from the Leaders Free trial presented yesterday at the conference.

The study, also published in the Journal of the American College of Cardiology, compared a month of DAPT therapy and either the BioFreedom biolimus A9-coated stent made by BioSensors International or its Gazelle BMS.

The nearly 2,500-patient trial had a composite primary safety endpoint of cardiac death, myocardial infarction or stent thrombosis and a primary efficacy endpoint of clinically driven target-lesion revascularization. The primary safety endpoint at two years was 12.6% for the BioFreedom-treated cohort, compared to 15.3% for the BMS group. The results for the primary efficacy endpoint were 6.8% for the BioFreedom arm versus 12.0% for the BMS arm.

Major bleeding occurred in 8.9% of the drug-coated stent group and 9.2% of the bare metal cohort. The rate of coronary thrombotic event was 8.2% for the DCS arm and 10.6% for BMS patients. Subsequent mortality was 27.1% a year after a major bleed and 26.3% a year after a thrombotic event.

“The 2-year results from the Leaders Free trial clearly show that the use of a polymer-free biolimus A9-coated stent was both significantly safer and more effective than a bare-metal stent for patients at high risk of bleeding treated with a 1-month course of DAPT,” lead investigator Dr. Philip Urban, of Geneva’s La Tour Hospital, said in prepared remarks. “These patients suffer from a persistently high incidence of bleeding and coronary thrombotic events, both of which are associated with a high and similar mortality over a 1-year period. Therefore, identification of predictors of both the composite primary safety event and major bleeding may help design future trials of DAPT duration for this population.”

Pages: Page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9

Filed Under: Cardiovascular, Stents Tagged With: TCT 2016, Transcatheter Cardiovascular Therapeutics symposium (TCT)

More recent news

  • Real-world data backs Route 92 reperfusion system
  • LivsMed unveils new surgical robot with telesurgery capabilities
  • JenaValve enrolls first patient in TAVR for AR study
  • HistoSonics expands insurance coverage for histotripsy treatment
  • Johnson & Johnson MedTech gets updated FDA nod for Varipulse PFA

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy